Molten Ventures

Bakhrom Ibragimov, a partner leading expansion across Central and Eastern Europe, built EBRD's venture-capital platform into a €500m program and combines public VC, private venture and tech investment banking experience.

Franco Danesi is a senior partner specializing in fintech who led Hokodo's €10m raise, has expertise in trade credit and B2B payments, and links European founders to Asian markets.

George Chalmers heads a dedicated climate franchise, pairing a CFA and six years of public-market equities experience at Credit Suisse with venture investing and first-hand energy‑tech founder experience.

Luke Smith, a Cambridge PhD in biochemistry who leads early investing at a publicly listed firm, brings institutional growth discipline to AI infrastructure—governance, security, compliance and observability for safe agents.

Malcolm Ferguson focuses on later-stage liquidity for European founders and early investors, combining Merrill Lynch, Morgan Stanley and GP Bullhound capital-markets experience with unusually public interview series on portfolio construction.

Nelly Markova combines CS training from TUM with an MBA from HBS and leads deep-tech investments in data infrastructure, AI and life sciences, backing companies like Evonetix and Zaptic.

Nic Brisbourne offers a rare founder-returned insider perspective—he founded a VC, took it public and rejoined post-acquisition in 2024; he runs The Equity Kicker and integrates mindfulness with founders.

Nick Sando, a fintech operator building a dedicated secondaries strategy, focuses on liquidity solutions for later-stage companies and early investors and backs financial infrastructure improving wellness and back-office simplicity.

Nicola McClafferty, founder‑CEO of Covetique (acquired by ASOS), brings an unusually hands-on operator's perspective to consumer deals, is her firm's go-to voice on AI, and led its recent rebrand.

Ozan Sonmez leads Central and Eastern Europe efforts, connecting Western European capital with high‑growth CEE engineering talent and applying late‑stage institutional discipline to earlier‑growth tech in CEE and Türkiye.

Richard Marsh is an entrepreneur and venture capital investor serving as Chief Portfolio Officer at Molten Ventures, where he invests and sits on portfolio company boards. He holds an Engineering degree and PhD from Cambridge University and an MBA from IMD, Lausanne, as a Sainsbury Management Fellow.

Steven Mendel focuses on secondaries, leveraging his founder/operator experience as ManyPets co-founder and CEO as part of a three-person team to position liquidity solutions for Europe’s private tech ecosystem.

Inga Deakin's Oxford and Cambridge neuroscience training plus experience at a US molecular diagnostics company informs investments in ML-driven healthtech using proprietary data to ease specialist shortages and overloaded workflows.

Phoebe Kitchen pairs investment banking, pension-fund and growth-stage VC experience to pursue a multi-decade infrastructure AI thesis to turn technology leadership into sustained advantage via customer love and durable defensibility.

Stuart Chapman is a transatlantic veteran who co-founded one of Europe’s first listed VC firms and champions a public VC model, with early investments in quantum computing and deep tech.

Alan Duncan brings 30+ years' experience and operator-level insight from boards of XMOS, Lime Microsystems and DisplayLink, plus electronics expertise and VC-standard shaping with the European Venture Capital Association.

Brian Caulfield, a serial founder-turned-VC, sold two tech companies for $81M, steered Aepona to a $120M Intel exit as interim CEO, and helped take his firm public raising £100M.

David Cummings blends R&D metallurgy experience in superconductors and titanium alloys with 16 years leading Lazard’s TMT group, investing as institutional VC and active angel in deep-tech and EIS co-investments.

Dr. Vishal Gulati is founder and managing partner at Recode Ventures, where he invests in AI-native biology and health companies. A physician-scientist with an MD and fellowship from the Academy of Medical Sciences, he has backed computational drug discovery platforms and companies including Turbine, Relation, Chemify, and LabGenius across Europe and the US. His work spans early-stage investments in digital health and genomics, with involvement extending beyond initial funding to support founders in translating scientific discoveries into commercial ventures.